Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | XIAP | P98170 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PLEC | Q15149 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6938800 | 0.94 | TSHR (0.34) | TSHRMEN1ALDH1A1KMT2ACA2 | |
| SCHEMBL6894066 | 0.81 | HCAR2 (0.36) | TSHRALDH1A1 | |
| SCHEMBL6895063 | 0.79 | CA1 (0.41) | KDM4EALDH1A1GAAKMT2ACA12 | |
| SCHEMBL20243323 | 0.79 | TSHR (0.37) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL3236904 | 0.79 | TSHR (0.37) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL17473201 | 0.79 | TSHR (0.37) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL19106187 | 0.78 | TSHR (0.36) | TSHR | |
| SCHEMBL6890550 | 0.78 | ALDH1A1 (0.48) | TSHRALDH1A1HPGD | |
| SCHEMBL577006 | 0.77 | — | — | |
| SCHEMBL302273 | 0.77 | TSHR (0.48) | TSHRKDM4EMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248941-A1 | Benzimidazone compound, process for producing the same, and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1437352-A1 | BENZIMIDAZOLE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248941-A1 | Benzimidazone compound, process for producing the same, and use thereof | SI, MLNR, FABP2 | TSHR 1588/4885KDM4E 755/4885MEN1 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.